Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2008
10/21/2008US7439250 such as lipoasparagine; liposomes
10/21/2008US7439249 such as 2-(7-acetylamino-1-furano-2-ylmethyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)-succinic acid; for treatment of autoimmune diseases, proliferative diseases, angiogenic disorders, and/or cancers; catheters, prosthetics
10/21/2008US7439248 5-[[4-[3-Methyl-4-oxo-3,4-dihydro-2-quinazolinyl]methoxy]phenyl-methyl]thiazolidine-2,4-dione or salt; compressed tablets; microcrystalline cellulose, magnesium stearate, lactose, or talc excipients; antidiabetic agents for non-insulin dependent diabetes; insulin sensitizers
10/21/2008US7439247 Bicyclic pyridine and pyrimidine P38 kinase inhibitors
10/21/2008US7439246 Fused heterocyclic kinase inhibitors
10/21/2008US7439245 e.g. 1-(3-Phenylsulfonyl-phenyl)piperazine; serotonin receptor modulator; anxiolytic agent, antidepressant, cognition activator; schizophrenia, obesity, Alzheimer's disease
10/21/2008US7439244 e.g. 8-(4-(4-Fluorobenzyl)-piperazin-1-yl)-3-phenylsulfonylquinoline; serotonin receptor modulator; antidepressant, anxiolytic agent, cognition activator; schizophrenia, obesity, Alzheimer's disease
10/21/2008US7439243 Piperazinyl-quinoline derivatives useful for the treatment of CNS disorders
10/21/2008US7439242 PPARγ modulators
10/21/2008US7439241 alpha 2 adrenergic receptor agonist in a topical carrier; amount sufficient to decrease blood flow through the small arteries or arterioles of the skin of the patient
10/21/2008US7439240 Reversible inhibitors of cysteine proteases S, K, F, L and B; inhibiting Cathepsin S; analgesics; 1-[9-(4-Chlorophenyl)-2-cyano-9H-purin-6-yl]-L-prolinamide for example
10/21/2008US7439239 delta-opioid receptor agonists as analgesics having reduced side effects and antagonists as immunosuppressants, antiinflammatory agents, neurological, psychiatric , urological and reproductive conditions; e.g. 10-(8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide
10/21/2008US7439238 Antiparasitic artemisinin derivatives (endoperoxides)
10/21/2008US7439237 e.g. 1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-oxo-2-[4-(2-piperidin-1-yl-ethyl)-piperidin-1-yl]-ethyl 4-(2-oxo-1 ,2,4,5-tetrahydro-benzo[d][1,3]diazepin-3-yl)-piperidine-1-carboxylate; calcitonin gene related peptide antagonist; migraine or cluster headaches, non-insulin-dependent diabetes
10/21/2008US7439236 Pharmaceutical composition for the treatment of CNS and other disorders
10/21/2008US7439235 Solid phase extraction; contacting with adsorption resin
10/21/2008US7439234 Administering Product R to maintain and improve production of white blood cells and platelets and to reduce gastrointestinal toxicity
10/21/2008US7439233 Vaccine for house dust mite allergen using naked DNA
10/21/2008US7439232 Heteroaryl 5-thio-β-D-glucopyranoside derivatives and therapeutic agents for diabetes containing the same
10/21/2008US7439077 Coumarin analog compounds for safer anticoagulant treatment
10/21/2008US7439059 Compositions and methods for activating genes of interest
10/21/2008US7439044 High viscosity xanthan polymer preparations
10/21/2008US7439031 contacting immortalized cells with test compounds and measuring poly/ADP-ribose/ polymerase (PARP) activation, to indicate anticarcinogenic activity; drug screening
10/21/2008US7438935 5.0%-70.0% by weight Radix Salviae Miltiorrhizae extract;10.0%-85.0% by weight Radix Notoginseng extract;5.0%-70.0% by weight Radix Astragali extract; and1.0%-15.0% by weight Borneol or oil of Lignum Dalbergiae Odoriferae; combined therapy with reduced side effects
10/21/2008US7438934 Administering extractsTribulus terrestris, Epimedium koreanum, Cinnamon cassia
10/21/2008US7438933 Maternal multi-nutrient against diabetes-related birth defects
10/21/2008US7438931 Methods and compositions for the treatment of angiogenic diseases
10/21/2008US7438930 Methylphenidate in a controlled release matrix coated with a hydrophobic acrylic polymer to retard release; enteric coating from an aqueous dispersion of an acrylic/methacrylic copolymer, a plasticizer and a glidant; topcoat of a second portion of the methylphenidate in immediate release form
10/21/2008US7438929 Multi-particulate form of medicament, comprising at least two differently coated forms of pellet
10/21/2008US7438927 Methods of treatment using a gastric retained gabapentin dosage
10/21/2008US7438926 Forming disruptions in stratum corneum layer of the skin to form pathways; causing the first agent and anti-healing agent to be fluxed through pathways for inhibiting a decrease in transdermal flux of a first agent
10/21/2008US7438925 Composed of therapeutic agent dispersed in modified, biologically active binders; agents used in coatings include paclitaxel, sirolimus; agents can be applied to surface of medical implant without using inert polymer carriers
10/21/2008US7438924 Dry granulated formulations of azithromycin
10/21/2008US7438905 administering a mixture of carriers and drugs that modulate signal transduction mediated by activation inducible lymphocyte immunomodulatory molecule (AILIM); immunosuppressants
10/21/2008US7438903 Fine particle sizes; nanostructure; in mixture with oil, water carriers, excipients; oral diseases; cognition activators; hypotensive agents; immunology diseases; blood disorders
10/21/2008US7438902 treating diabetes mellitus; isolating a nestin-positive pancreatic stem cell from a pancreatic islet of a donor; transferring the stem cell into the patient, wherein it differentiates into an insulin-producing cell; across allogeneic or xenogeneic barriers and graft rejection does not occur
10/21/2008US7438900 Dendritic encapsulation of active agents
10/21/2008US7438899 Gastrointestinal disorders; anticancer agents; sustained release
10/21/2008US7438896 Method of skin care using lipoic and ascorbic acids
10/21/2008US7438203 Dermal penetration enhancers and drug delivery systems involving same
10/21/2008CA2468847C Crystalline form of a ribofuranosyluronamide derivative; a human adenosine a2a receptor agonist
10/21/2008CA2444587C Pharmaceutical compositions of low salt polyallylamine hydrochloride
10/21/2008CA2438294C Pyridopyrimidine or naphthyridine derivative
10/21/2008CA2412708C Sulfur containing dermatological compositions and methods for reducing malodors in dermatological compositions
10/21/2008CA2390284C Apparatus and method for preparing microparticles
10/21/2008CA2387383C Use of anti-ferritin monoclonal antibodies in the treatment of some cancers
10/21/2008CA2368823C Use of dopamine d3 receptor ligands for producing medicaments for treating kidney disorders
10/21/2008CA2357038C Medical compositions comprising 1,4-benzothiazepine derivatives for the treatment of atrial fibrillation
10/21/2008CA2351947C Hyperforin as cytostatic agent and hyperforin ointment or cream as application form
10/21/2008CA2340734C Optically active pyridyl-4h-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases
10/21/2008CA2336624C Farnesyl protein transferase inhibitors with in vivo radiosensitizing properties
10/21/2008CA2333648C Thermoprotected microparticle compositions and process for terminal steam sterilization thereof
10/21/2008CA2331408C Fatty analogues for the treatment of obesity, hypertension and fatty liver
10/21/2008CA2296732C Polyhydroxyalkylpyrazine derivatives, their preparation and medicines containing them
10/21/2008CA2296012C Epothilone derivatives
10/21/2008CA2293346C Device and method for treatment of dysmenorrhea
10/21/2008CA2282345C Pharmaceutical composition
10/21/2008CA2270893C N-aryl substituted tetrahydroquinolines ligands for retinoid receptors having agonist, antagonist or inverse agonist type activity
10/21/2008CA2247998C Fragments of cr1 and their use
10/21/2008CA2232294C Bioactive factors of aloe vera plants
10/21/2008CA2230452C Novel 3' terminal sequence of hepatitis c virus genome and diagnostic and therapeutic uses thereof
10/21/2008CA2220226C Improved methods for transfecting t cells
10/21/2008CA2210913C Antipsychotic 4-(1h-indolyl-1-yl)-1-substituted piperidine derivatives
10/21/2008CA2205347C Lazaroids-based compositions and method for preventing adhesion formation using the same
10/21/2008CA2174472C Arylalkylpyridazinones
10/21/2008CA2171334C Substituted thiazolo[3,2-a]azepine derivatives
10/21/2008CA2169071C Methods for modulating the human sexual response
10/21/2008CA2162361C Antisense oligonucleotides which combat aberrant splicing and methods of using the same
10/21/2008CA2146707C Substituted n-heteroaroylguanidines as inhibitors of na+/h+ exchange
10/20/2008CA2629419A1 Dietary supplement for the compensation of nutritional deficiency
10/18/2008CA2682189A1 Thiazole and thiophene analogues, and their use in treating autoimmune diseases and cancers
10/18/2008CA2583716A1 Oral dosage formulations of protease resistant polypeptides
10/16/2008WO2008124850A1 Fused ring heterocycle kinase modulators
10/16/2008WO2008124849A2 Pyrrolo-pyridine kinase modulators
10/16/2008WO2008124848A1 Fused ring heterocycle kinase modulators
10/16/2008WO2008124842A1 Treatments with helminths
10/16/2008WO2008124838A1 Compounds that inhibit human dna ligases and methods of treating cancer
10/16/2008WO2008124836A2 Methods of reducing virulence in bacteria
10/16/2008WO2008124828A1 Methods for treating vascular disruption disorders
10/16/2008WO2008124826A1 Methods for treating cancer
10/16/2008WO2008124824A1 Dosages and methods for the treatment of cancer
10/16/2008WO2008124823A1 Method of treating melanoma
10/16/2008WO2008124822A1 Method of treating brain cancer
10/16/2008WO2008124821A1 Antibacterial 1,4,5-substituted aminoglycoside analogs
10/16/2008WO2008124815A1 Method of activating nk cells
10/16/2008WO2008124814A2 Sublingual formulations of d-cycloserine and methods of using same
10/16/2008WO2008124803A1 Substituted deuterium enriched thiophenes for the treatment of hypertension
10/16/2008WO2008124757A1 Thiazolyl compounds useful as kinase inhibitors
10/16/2008WO2008124756A1 Compositions and methods for treating bone cancer
10/16/2008WO2008124745A1 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
10/16/2008WO2008124729A1 One-pot synthesis of alpha/beta-o-glycolipids
10/16/2008WO2008124703A2 Development of molecular imaging probes for carbonic anhydrase-ix using click chemistry
10/16/2008WO2008124699A1 A method of using proteasome inhibitors in combination with histone deacetylase inhibitors to treat cancer
10/16/2008WO2008124691A1 Glufosfamide combination therapy
10/16/2008WO2008124681A2 Methods and systems for treating cell proliferation disorders
10/16/2008WO2008124665A1 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
10/16/2008WO2008124614A1 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
10/16/2008WO2008124611A1 Pharmaceutical compositions comprising ramipril and indapamide
10/16/2008WO2008124610A1 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
10/16/2008WO2008124582A1 Renin inhibitors
1 ... 3036 3037 3038 3039 3040 3041 3042 3043 3044 3045 3046 3047 3048 3049 3050 3051 3052 3053 3054 3055 3056 ... 7860